ECPU-0001 BCL-2 inhibitor (RGNCY-0119)
Per 10 mg
ECPU-0001 is a potent BCL-2 targeting agent(as confirmed by molecular docking) with effective anticancer activity. ECPU-0001 exerts a significant cytotoxic effect against lung adenocarcnima cells (A459, IC50=1.779µM). ECPU-0001 induces apoptosis in A459 cells by targeting BC:L-2. The administration of ECPU-0001 to to tumor xenograft models resulted in an inhibition of tumor growth without exerting severe toxicity. Therefore, ECPU-0001 may provide a new avenue for lung adenocarcinoma therapy.
Systematic Name: 1-(9-ethyl-9H-carbazol-3-yl)-3-(2-(4-(furan-2-carbonyl)piperazin-1-yl)ethyl)urea
Mol Wt: 459.55
Mongre RJ. et al. Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma In Vitro and Xenograft Mice Model. Cancers 2019, 11, 1245; doi:10.3390/cancers11091245.
There are no uploaded files